View Print Version
More from GlobeNewswire

Medigene announces market launch of Veregen® in Belgium, Denmark and Finland

By GlobeNewswire,  June 12, 2014, 02:05:00 AM EDT

Medigene AG / Medigene announces market launch of Veregen® in Belgium, Denmark and Finland . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Martinsried/Munich, 12 June 2014. Medigene AG (MDG1, Frankfurt, Prime Standard) announces market launches of Veregen® in further three European markets. Medigene's marketing partner Will-Pharma has launched the drug for the treatment of genital warts in Belgium and the marketing partner Azanta A/S will start the launch of Veregen® in Denmark and Finland within the next few weeks.

Veregen® is already available in the USA, in 12 European countries (Germany, Austria, Switzerland, Spain, the Netherlands, Norway, Sweden, the Czech Republic, Poland, Serbia, Hungary, Slovakia) and Taiwan. Market approvals for Veregen® have been granted in a number of other countries. Further market launches and approvals of Veregen® are expected in 2014. Several marketing agreements have been concluded in Europe, Asia, and America.

About Veregen®: Veregen®, a topical treatment for external genital or perianal warts, contains a concentrate of catechins with a complex defined composition extracted from green tea leaves. In its current treatment guidelines for sexually transmitted diseases, the US Center for Disease Control and Prevention recommends Sinecatechins 15% ointment (Veregen®) as a possible option for treating genital warts. In addition, Sinecatechins 10% & 15% ointment (Veregen®) has been included in the current European guideline on the treatment of genital warts, the 2012 European Guideline for the Management of Anogenital Warts.

About Will-Pharma: Will-Pharma markets and promotes its own ethical products, food supplements and medical devices through its well trained sales force. With its head offices in the three countries of Benelux, Will-Pharma has more than 90 years of experience in the development and sale of drugs, medical devices, and food supplements. Moreover, Will-Pharma has a long standing distribution agreement with Daiichi-Sankyo. More information on Will-Pharma:

About Azanta: Azanta A/S is a privately owned specialty pharma company primarily operating within oncology, women's and men's health, and addiction medicine. The vision of Azanta A/S is to become an international market leader for specialty pharma products and innovative pharmaceutical products. Azanta A/S currently markets nine specialty pharma products, including Nimoral, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy. In addition, Azanta A/S has a portfolio of low-risk development projects for commercialization in the near term. For further information, please visit

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partners. Medigene has various drug candidates in clinical development and it is developing highly innovative treatment platforms. For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene®, Veregen®, EndoTAG® and RhuDex®are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.


Julia Hofmann, Claudia Burmester

Tel.: +49 - 89 - 20 00 33 - 33 01


To unsubscribe from the press release distribution list, please go to:

Press release as PDF

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Medigene AG via Globenewswire


This article appears in: News Headlines

Latest News Video

Most Active by Volume

Company Last Sale Change Net / %
RAD $ 6.69 0.36 ▼ 5.11%
SIRI $ 3.38 0.06 ▼ 1.74%
AAPL $ 99.02 1.35 ▲ 1.38%
FB $ 74.92 0.27 ▼ 0.36%
BAC $ 15.50 0.09 ▼ 0.58%
MU $ 31.98 1.44 ▼ 4.31%
GE $ 25.59 0.20 ▼ 0.78%
DLTR $ 54.87 0.65 ▲ 1.20%

As of 7/28/2014, 04:05 PM